YPL136W Antibody

What is YPL136W and where is it expressed?

YPL136W is a gene that encodes a putative uncharacterized protein in Saccharomyces cerevisiae (Baker's yeast), specifically in strain 204508/S288c. While its precise function remains to be fully characterized, it is part of the yeast genome and represents one of the open reading frames (ORFs) identified in the region between ELP3 and PEP4 loci, as noted in genomic studies. The protein is classified as "putative uncharacterized" in current databases, indicating that its biological role requires further investigation. Expression analysis would typically involve using techniques such as Western blotting with specific antibodies, RT-PCR for transcript detection, or proteomic approaches to determine its presence across different growth conditions and cellular compartments .

What applications are supported by commercially available YPL136W antibodies?

Commercial YPL136W antibodies, such as the rabbit polyclonal antibody, have been validated for several research applications. According to available information, these applications primarily include Enzyme-Linked Immunosorbent Assay (ELISA) and Western Blot (WB) techniques. The antibody has been specifically developed for detection of the YPL136W protein from Saccharomyces cerevisiae (strain 204508/S288c). When conducting Western blots, the antibody allows for specific identification of the antigen in complex protein mixtures. For optimal results in these applications, antigen-affinity purified antibody preparations are typically used, ensuring higher specificity when detecting the target protein .

What are the recommended storage conditions for YPL136W antibodies?

YPL136W antibodies, like most research-grade antibodies, require specific storage conditions to maintain their functionality and specificity. While specific information for YPL136W antibody storage is not detailed in the provided search results, standard practices for polyclonal IgG antibodies generally apply. These antibodies should typically be stored at -20°C for long-term preservation, with aliquoting recommended to avoid repeated freeze-thaw cycles that can degrade antibody quality. For short-term storage (1-2 weeks), refrigeration at 4°C is typically acceptable. Storage buffers often contain preservatives such as sodium azide at low concentrations (0.02-0.05%) to prevent microbial growth, though care must be taken as sodium azide can inhibit peroxidase activity in certain detection systems. When working with the antibody, it should be kept on ice and returned to appropriate storage promptly after use to maximize shelf life and performance consistency across experiments.

How can I optimize ChIP protocols specifically for YPL136W?

Optimization of Chromatin Immunoprecipitation (ChIP) protocols for YPL136W requires careful consideration of several parameters. Based on related research with yeast proteins, successful ChIP experiments with YPL136W antibody would necessitate proper crosslinking, sonication optimization, and appropriate antibody concentrations. In research utilizing ChIP for other yeast proteins such as Htz1, protocols have been established that could be adapted for YPL136W studies. For instance, ChIP analysis with anti-Htz1 antibody for investigating association to promoters of genes like GAL1, SWR1, and ribosomal protein genes provides a methodological framework. When optimizing a ChIP protocol for YPL136W, researchers should start with a crosslinking time of 10-15 minutes using 1% formaldehyde, followed by sonication to achieve chromatin fragments of 200-500bp. The antibody concentration should be titrated, typically starting with 2-5μg per reaction, and incubation performed overnight at 4°C with rotation. Including appropriate controls, such as input DNA and IgG controls, is essential for quantification and specificity verification .

What are the key considerations for validating YPL136W antibody specificity?

Validating the specificity of YPL136W antibody is crucial for ensuring reliable experimental outcomes. A comprehensive validation approach should include multiple complementary techniques. First, Western blot analysis using both wild-type yeast extracts and YPL136W deletion mutants (if available) should be performed to confirm the antibody recognizes a band of the expected molecular weight only in wild-type samples. Second, immunoprecipitation followed by mass spectrometry can identify which proteins are pulled down by the antibody, confirming whether YPL136W is the primary target. Third, peptide competition assays, where the antibody is pre-incubated with purified YPL136W peptide/protein before application to samples, should eliminate specific signal if the antibody is truly specific. Fourth, immunofluorescence microscopy comparing wild-type and knockout strains can provide spatial validation of specificity. Finally, cross-reactivity testing against related proteins or in different yeast strains would establish the boundaries of antibody specificity .

How does sample preparation affect YPL136W detection in different experimental contexts?

Sample preparation significantly impacts YPL136W detection across various experimental platforms. For Western blot applications, protein extraction methods must effectively solubilize YPL136W while preserving its epitopes. Based on protocols used for similar yeast proteins, extracting proteins using methods described for PNGase activity assays could be adapted, where cells (total OD600 ~ 40) are processed through established extraction methods. For immunoprecipitation, lysis buffers containing appropriate detergents (typically 0.5-1% NP-40 or Triton X-100) with protease inhibitors are essential. When analyzing protein modifications, such as in studies of PNGase F treatment effects on immunoprecipitated samples, division of samples into treated and untreated aliquots allows for comparative analysis of post-translational modifications. For quantitative analyses, standard curves using recombinant proteins can help establish detection limits and quantitative relationships. Additionally, sample preparation should account for protein localization, as differential centrifugation or specific extraction methods may be needed depending on whether YPL136W is membrane-associated, cytosolic, or nuclear .

What are the optimal dilutions and conditions for YPL136W antibody in Western blotting?

For optimal Western blotting results with YPL136W antibody, several technical parameters must be carefully controlled. Based on standard protocols for similar yeast protein antibodies, primary antibody dilutions typically range from 1:500 to 1:2000, though specific optimization is recommended for each new lot of antibody. Blocking should be performed with 5% non-fat dry milk or BSA in TBST for 1 hour at room temperature to minimize background. For protein extraction, methods similar to those described in related yeast protein studies are recommended, where approximately 20 μg of total protein extract should be loaded per lane after preparation according to established protocols. Following SDS-PAGE separation on 10% gels, proteins should be transferred to nitrocellulose membranes using standard transfer conditions (100V for 1 hour or 30V overnight at 4°C). Primary antibody incubation should be performed overnight at 4°C, followed by appropriate secondary antibody (typically anti-rabbit IgG at 1:2000-1:5000 dilution) for 1 hour at room temperature. Visualization can be achieved through chemiluminescence detection systems with exposure times determined empirically based on signal strength .

How can I troubleshoot non-specific binding when using YPL136W antibody?

Non-specific binding is a common challenge when working with antibodies against yeast proteins like YPL136W. To address this issue, a systematic troubleshooting approach is recommended. First, increase the stringency of your blocking solution by trying different blockers (5% BSA, 5% milk, commercial blockers) or by adding 0.1-0.5% Tween-20 to reduce hydrophobic interactions. Second, optimize antibody dilution, as too concentrated antibody solutions often increase background; perform a dilution series to identify the optimal concentration that maintains specific signal while reducing background. Third, incorporate additional washing steps with increased salt concentration (up to 500mM NaCl) in TBST buffer to disrupt weak non-specific interactions. Fourth, pre-absorb the antibody with acetone powder prepared from the YPL136W knockout strain to remove antibodies that recognize other yeast proteins. Fifth, consider using alternative detection systems, as some secondary antibodies or detection reagents may contribute to background. Finally, for critical applications, affinity purification of the antibody against the specific epitope can dramatically improve specificity .

What controls should be included when using YPL136W antibody in immunoprecipitation experiments?

When conducting immunoprecipitation (IP) experiments with YPL136W antibody, proper controls are essential for result validation and troubleshooting. A comprehensive set of controls should include: 1) Input control - a small aliquot (typically 5-10%) of the pre-cleared lysate before antibody addition to confirm target protein presence in starting material; 2) IgG control - normal rabbit IgG used in parallel IP reactions to identify non-specific binding; 3) No-antibody control - beads only, to detect proteins binding directly to the matrix; 4) Knockout/knockdown control - when available, lysate from YPL136W deletion strain to confirm signal specificity; 5) Competing peptide control - pre-incubation of antibody with excess target peptide to block specific binding sites; 6) Reciprocal IP - if antibodies to known interacting partners are available, confirming interactions through reverse IP; 7) Denaturing controls - comparing native versus denaturing conditions to distinguish direct versus indirect interactions. For validation of results, techniques such as mass spectrometry analysis of immunoprecipitated proteins can provide unbiased confirmation of target enrichment .

How should quantitative data from YPL136W antibody experiments be normalized?

Quantitative data analysis from experiments using YPL136W antibody requires careful normalization to ensure accurate interpretation. For Western blot quantification, several normalization approaches should be considered. First, housekeeping proteins (such as actin or GAPDH in yeast) should be used as loading controls, with target protein signal normalized to the corresponding loading control signal in each lane. Second, for chromatin immunoprecipitation experiments, data should be expressed as percentage of input DNA, as demonstrated in studies of chromatin-associated proteins. For instance, in ChIP analysis of Htz1 association with promoters, results were reported as percentage of input DNA obtained by ChIP with anti-Htz1 antibody, with data points representing mean ± standard deviation from at least three independent experiments. Third, when analyzing transcript levels in deletion mutants, normalization to a reference gene (such as ACT1) is standard practice, as shown in the analysis of RDS1 and UBX3 in arp6- and htz1-deletion mutants. Fourth, for absolute quantification, standard curves using recombinant proteins at known concentrations should be included. Finally, statistical analysis should incorporate appropriate tests based on data distribution, with biological replicates (n≥3) rather than technical replicates to account for biological variability .

What criteria determine whether YPL136W antibody detection is specific and reliable?

Establishing specificity and reliability for YPL136W antibody detection requires meeting several critical criteria across different experimental platforms. First, size specificity must be confirmed via Western blot, where the antibody should detect a single band at the predicted molecular weight for YPL136W (or a pattern consistent with known post-translational modifications). Second, signal absence in negative controls is essential - the antibody should show minimal or no signal when tested against YPL136W deletion strains or after pre-absorption with the immunizing peptide/protein. Third, reproducibility across experimental replicates must be demonstrated, with consistent detection patterns in independent experiments. Fourth, concordance between different detection methods provides strong validation - results from Western blot, immunofluorescence, and immunoprecipitation should show coherent patterns of expression and localization. Fifth, lot-to-lot consistency should be assessed when using new antibody preparations. Sixth, cross-reactivity testing should confirm minimal binding to related proteins or proteins from distant species. Finally, functional validation, where antibody application (e.g., in immunodepletion experiments) produces expected functional consequences, provides the strongest evidence for specificity and reliability .

How can YPL136W antibody be utilized in studying protein-protein interactions?

YPL136W antibody can serve as a valuable tool for investigating protein-protein interactions through several complementary approaches. Co-immunoprecipitation (Co-IP) represents the primary method, where YPL136W antibody is used to pull down the target protein along with its interacting partners from cell lysates under native conditions. The immunoprecipitated complex can then be analyzed by Western blotting with antibodies against suspected interaction partners or by mass spectrometry for unbiased discovery of the entire interactome. Proximity ligation assays (PLA) offer an alternative approach, where YPL136W antibody is used alongside antibodies against potential interacting proteins to visualize interactions in situ with single-molecule resolution. For confirmation of direct interactions, far-Western analysis can be employed, where proteins separated by SDS-PAGE and transferred to membranes are probed with purified YPL136W protein followed by YPL136W antibody detection. Yeast two-hybrid validation can complement these approaches, though this is antibody-independent. For dynamic interaction studies, FRET or BRET analyses using fluorescently-tagged proteins can be validated using antibody-based approaches to confirm expression levels. Crosslinking immunoprecipitation (CLIP) can also capture transient interactions before immunoprecipitation with the YPL136W antibody .

What experimental design considerations are important when using YPL136W antibody in ChIP-seq studies?

ChIP-seq studies using YPL136W antibody require careful experimental design to generate reliable, interpretable data. First, antibody quality is paramount - the YPL136W antibody must demonstrate high specificity and enrichment capability in preliminary ChIP-qPCR experiments before proceeding to sequencing. Second, appropriate controls must be included: input DNA (pre-immunoprecipitation), IgG control immunoprecipitations, and ideally, samples from YPL136W deletion strains as negative controls. Third, biological replicates (minimum three) are essential for statistical validation of binding sites. Fourth, sequencing depth must be sufficient - typically 20-30 million uniquely mapped reads per sample for factors with few binding sites, with greater depth for factors with numerous binding sites. Fifth, spike-in normalization using chromatin from a different species (e.g., Drosophila) should be considered for comparative studies. Sixth, peak calling parameters must be optimized based on expected binding patterns (sharp peaks vs. broad domains). Finally, validation of identified binding sites through ChIP-qPCR of selected loci provides important quality control. For data analysis, correlation with transcriptomic data (RNA-seq) and integration with other epigenomic features can provide functional insights into YPL136W binding patterns .

How do different fixation and extraction protocols affect YPL136W antibody performance?

The choice of fixation and extraction protocols significantly impacts YPL136W antibody performance across different experimental applications. Table 1 outlines the comparative effectiveness of common protocols based on research with similar yeast proteins:

The optimal protocol selection depends on the specific research question and application. For instance, studies focusing on protein modifications, such as those examining PNGase F treatment effects on immunoprecipitated samples, benefit from protocols that preserve post-translational modifications. Similarly, quantitative analyses require standardized extraction efficiency, often achieved through controlled cell disruption methods where cells (total OD600 ~ 40) are processed consistently .

What are the most common technical issues and solutions when working with YPL136W antibody?

Researchers working with YPL136W antibody may encounter several technical challenges. Table 2 provides a comprehensive troubleshooting guide:

When troubleshooting specific applications, researchers should consider the unique properties of yeast cells and proteins. For instance, the rigid cell wall of yeast requires special consideration during lysis procedures, and the relatively low abundance of many yeast proteins may necessitate optimization of enrichment protocols. Additionally, when analyzing protein modifications, such as in studies involving PNGase F treatment of immunoprecipitated samples, researchers should divide samples into treated and untreated aliquots to establish clear comparative baselines .

What emerging technologies might enhance YPL136W protein characterization beyond current antibody-based methods?

The landscape of protein characterization is rapidly evolving beyond traditional antibody-based approaches, offering new opportunities for YPL136W research. CRISPR-Cas9 genome editing enables endogenous tagging of YPL136W with fluorescent proteins or epitope tags, allowing real-time visualization and purification without relying on antibody specificity. Proximity-dependent biotin identification (BioID) and APEX2 proximity labeling can map the protein neighborhood of YPL136W by expressing it as a fusion with biotin ligase, identifying interacting proteins through streptavidin pulldown and mass spectrometry. Advanced mass spectrometry techniques, particularly data-independent acquisition (DIA) methods, allow label-free quantification of YPL136W across different conditions without antibody limitations. Single-cell proteomics technologies can reveal cell-to-cell variation in YPL136W expression levels and modifications. Cryo-electron microscopy, if YPL136W is part of a larger complex, can elucidate structural details at near-atomic resolution. Computational approaches, including AlphaFold2 and RoseTTAFold, can predict YPL136W structure with increasing accuracy. Finally, synthetic antibody alternatives such as nanobodies, affimers, and aptamers offer potential advantages in specificity, size, and ease of production compared to traditional antibodies .

How might integrative multi-omics approaches enhance our understanding of YPL136W function?

Integrative multi-omics approaches represent a powerful frontier for comprehensively understanding YPL136W function beyond what any single technique can reveal. A coordinated strategy might begin with transcriptomic analysis (RNA-seq) in wild-type versus YPL136W deletion strains to identify genes affected by its absence, followed by ChIP-seq using YPL136W antibody to map its genomic binding sites, potentially revealing direct regulatory targets. Proteomics using techniques like TMT labeling and mass spectrometry could quantify proteome-wide changes resulting from YPL136W deletion, while interactome analysis through affinity purification-mass spectrometry would identify physical interaction partners. Metabolomic profiling could reveal metabolic pathways affected by YPL136W deletion. Phosphoproteomics and other PTM analyses would identify modifications on YPL136W itself and changes in cellular signaling networks. Chromatin accessibility assays (ATAC-seq) might reveal how YPL136W influences chromatin structure. Mathematical modeling using Bayesian networks or machine learning approaches could integrate these diverse datasets to predict functional relationships and generate testable hypotheses about YPL136W's cellular role. This integrative approach would be particularly valuable given that YPL136W is currently classified as a "putative uncharacterized protein," suggesting significant knowledge gaps that multi-dimensional analysis could help address .